Endometrial Cancer Risk Reduced With Oral Bisphosphonate Use

Share this content:
Endometrial Cancer Risk Reduced With Oral Bisphosphonate Use
Endometrial Cancer Risk Reduced With Oral Bisphosphonate Use

(HealthDay News) — For postmenopausal women, oral bisphosphonate use is associated with a reduction in the risk for endometrial cancer, according to a study published in the Journal of Clinical Oncology.

Polly A. Newcomb, PhD, from the Fred Hutchinson Cancer Research Center in Seattle, and colleagues examined the correlation between oral bisphosphonate use and the risk of endometrial cancer in a cohort of 89,918 postmenopausal women. 

At baseline, a detailed health interview was conducted, and an inventory of regularly used medications was reviewed to ascertain bisphosphonate use at baseline and during follow-up.

The researchers found that 1,123 women were diagnosed with incident invasive endometrial cancer during a median follow-up of 12.5 years. There was a reduction in the risk for endometrial cancer with ever use of bisphosphonates (adjusted HR=0.8; 95% CI, 0.6-1.00; P=.05); no interactions were seen with age, BMI or indication for use.

"In summary, our findings suggest that use of bisphosphonates is modestly associated with reduced endometrial cancer risk, a finding consistent with the inverse association between use of this medication and breast cancer risk," the researchers wrote.

One author disclosed financial ties to the pharmaceutical industry.

Reference

  1. Newcomb PA et al. J Clin Oncol. 2015;doi:10.1200/JCO.2014.58.6842.
You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus